Table 2 GO and KEGG pathway analysis that hub genes were enriched in
Traits | Enrichment | Type | Gene symbol |
|---|---|---|---|
DMD | Immune response | BP | IRF8,CD33,C3AR1,TLR7,TYROBP,AIF1 |
Myeloid leukocyte activation | BP | CD33,C3AR1,TLR7,TYROBP,AIF1 | |
Regulated exocytosis | BP | CD33,C3AR1,PLEK,TYROBP | |
Cell activation | BP | CD33,C3AR1,TLR7,PLEK,TYROBP,AIF1 | |
Neutrophil degranulation | BP | CD33,C3AR1,TYROBP | |
Neutrophil activation involved in immune response | BP | CD33,C3AR1,TYROBP | |
Defense response | BP | IRF8,C3AR1,TLR7,TYROBP,AIF1 | |
Neutrophil activation | BP | CD33,C3AR1,TYROBP | |
Neutrophil mediated immunity | BP | CD33,C3AR1,TYROBP | |
Granulocyte activation | BP | CD33,C3AR1,TYROBP | |
Secretory vesicle | CC | CD33,C3AR1,TYROBP | |
Secretory granule | CC | CD33,C3AR1,TYROBP | |
Lysosome | CC | C3AR1,TLR7 | |
Lytic vacuole | CC | C3AR1,TLR7 | |
Vacuolar part | CC | C3AR1,TLR7 | |
Cytoplasmic vesicle part | CC | CD33,C3AR1,TLR7,TYROBP | |
Vacuole | CC | C3AR1,TLR7 | |
Ruffle | CC | PLEK;AIF1 | |
Whole membrane | CC | CD33,C3AR1,TLR7 | |
Protein-containing complex binding | MF | AIF1 | |
Lipid binding | MF | PLEK | |
Staphylococcus aureus infection | KEGG | C3AR1 | |
Pertussis | KEGG | IRF8 | |
BMD | Collagen fibril organization | BP | COL5A1,LOX,ADAMTS2 |
Extracellular matrix organization | BP | CTSK,COL5A1,ELN,LOX | |
Positive regulation of phosphatase activity | BP | PLEK | |
Positive regulation of integrin activation | BP | PLEK | |
Extracellular structure organization | BP | CTSK,COL5A1,ELN,LOX,ADAMTS2 | |
Cell adhesion | BP | THBS2;PLEK,COL5A1 | |
Biological adhesion | BP | THBS2,PLEK,COL5A1 | |
Extracellular matrix | CC | THBS2,COL5A1,ELN,LOX,ADAMTS2 | |
Collagen-containing extracellular matrix | CC | THBS2,COL5A1,ELN,ADAMTS2 | |
Basement membrane | CC | THBS2,COL5A1 | |
Extracellular matrix component | CC | COL5A1 | |
Cell projection part | CC | PLEK | |
Plasma membrane bounded cell projection part | CC | PLEK | |
Extracellular matrix structural constituent | MF | COL5A1,ELN,THBS2 | |
Structural molecule activity | MF | COL5A1,ELN,THBS2 | |
Protein kinase C binding | MF | PLEK | |
Magnesium ion binding | MF | CDK2 | |
Fibronectin binding | MF | CTSK | |
p53 signaling pathway | KEGG | CDK2,BCL2L1 | |
Protein digestion and absorption | KEGG | COL5A1,ELN | |
Rheumatoid arthritis | KEGG | CTSK | |
Amyotrophic lateral sclerosis (ALS) | KEGG | BCL2L1 | |
PI3K-Akt signaling pathway | KEGG | THBS2,CDK2,BCL2L1 | |
BMD age | Collagen fibril organization | BP | COL5A1,COL14A1,ADAMTS2 |
Endodermal cell differentiation | BP | COL5A1 | |
Extracellular matrix organization | BP | COL5A1,COL14A1,ADAMTS2 | |
Endoderm formation | BP | COL5A1 | |
Extracellular structure organization | BP | COL5A1,COL14A1,ADAMTS2 | |
Endoderm development | BP | COL5A1 | |
Extracellular matrix | CC | COL5A1,COL14A1,ADAMTS2 | |
Collagen-containing extracellular matrix | CC | COL5A1,COL14A1,ADAMTS2 | |
Extracellular matrix component | CC | COL5A1,COL14A1 | |
Extracellular matrix structural constituent | MF | COL5A1,COL14A1 | |
DNA binding, bending | MF | COL5A1,COL14A1 | |
Structural molecule activity | MF | COL5A1,COL14A1 | |
Extracellular matrix structural constituent conferring tensile strength | MF | COL5A1,COL14A1 | |
Protein digestion and absorption | KEGG | COL5A1,COL14A1 |